Back

Dose titration among patients receiving vericiguat in real-world clinical practice and association with clinical outcomes and health care resource use

29 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Approaches to declining ejection fraction Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Andrew Ambrosy

Kaiser Permanente, San Francisco Medical Centre and Medical Offices, San Francisco (United States of America)

6 More presentations in this session

Presentation thumbnail
Guideline-directed medication therapy use among patients with HFrEF receiving vericiguat: comparing findings from a real-world study to clinical trials
Doctor A. Ambrosy (San Francisco, US)
Abstract Slides Video
Presentation thumbnail
Impact of comprehensive heart failure management initiated during hospitalization on clinical outcomes in patients with decompensated heart failure with reduced ejection fraction
Associate Professor R. Christodorescu (Timisoara, RO)
Abstract Slides Video
Presentation thumbnail
Residual risk of hospitalization & all-cause mortality among patients with heart failure with reduced ejection fraction without worsening heart failure who received guideline-directed medical therapy
Doctor A. Stevenson (Chatham, US)
Abstract Slides Video
Presentation thumbnail
Cardiac cGMP augmentation and hemodynamic improvement in heart failure with reduced ejection fraction: evidence from sacubitril/valsartan and vericiguat treatment
Doctor T. Inoue (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Association of myocardial damage assessed by 99mTc-MIBI scintigraphy with exercise capacity and clinical outcomes in patients with heart failure
Doctor H. Mima (Suita, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Approaches to declining ejection fraction

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.
thumbnail
Congress Presentation
Impact of worsening heart failure events and renal impairment on vericiguat drug use patterns in real-world care
thumbnail
Congress Presentation
VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure and VICTORIA: Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources